Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Last Name

Contact Us
If you have any questions or feedback please contact us.


Search Results to Mark Boguniewicz

This is a "connection" page, showing the details of why an item matched the keywords from your search.


One or more keywords matched the following items that are connected to Boguniewicz, Mark

Item TypeName
Academic Article Advances in allergic skin diseases.
Academic Article A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group.
Academic Article Topical treatment of atopic dermatitis.
Academic Article The economics of topical immunomodulators for the treatment of atopic dermatitis.
Academic Article Update on atopic dermatitis: insights into pathogenesis and new treatment paradigms.
Academic Article Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: results from a randomized, double-blind, vehicle-controlled study.
Academic Article Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents.
Academic Article Cost-effectiveness analysis of tacrolimus ointment versus high-potency topical corticosteroids in adults with moderate to severe atopic dermatitis.
Academic Article 1% pimecrolimus cream for atopic dermatitis.
Academic Article 10. Atopic dermatitis.
Academic Article Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology.
Academic Article A multiple-domain framework of clinical, economic, and patient-reported outcomes for evaluating benefits of intervention in atopic dermatitis.
Academic Article Atopic dermatitis.
Concept Administration, Topical
Academic Article The ABC's of managing patients with severe atopic dermatitis.
Academic Article Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11?years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial.

Search Criteria
  • Administration Topical

Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)